3 results match your criteria: "Bagamoyo Research and Training Centre of Ifakara Health Institute[Affiliation]"
The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.
Malar J
February 2015
Eberhard Karls Universität Tübingen, Institut für Tropenmedizin, Wilhelmstraße 27, 72074, Tübingen, Germany.
Background: The malaria vaccine RTS,S induces antibodies against the Plasmodium falciparum circumsporozoite protein (CSP) and the concentration of Immunoglobulin G (IgG) against the repeat region of CSP following vaccination is associated with protection from P. falciparum malaria. So far, only the quantity of anti-CSP IgG has been measured and used to predict vaccination success, although quality (measured as avidity) of the antigen-antibody interaction shall be important since only a few sporozoites circulate for a short time after an infectious mosquito bite, likely requiring fast and strong binding.
View Article and Find Full Text PDFArticle Synopsis
- The RTS,S/AS malaria vaccine is being studied for inclusion in the WHO's Expanded Programme on Immunization, with safety and effectiveness evaluated over 20 months after the initial nine-month surveillance.
- In a Tanzanian trial with 340 infants, both RTS,S/AS02(D) and the hepatitis B vaccine were administered, revealing a similar safety profile with no significant adverse vaccine-related events.
- By month 20, 71.8% of RTS,S recipients had protective antibody levels against malaria, showing a vaccine efficacy of approximately 50.7% at 12 months, though efficacy was less clear at 18 months with a rate of 26.7%.
Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
N Engl J Med
December 2008
Bagamoyo Research and Training Centre of Ifakara Health Institute, Bagamoyo, Tanzania.
Background: The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Organization's Expanded Program on Immunization (EPI). We assessed the feasibility of integrating RTS,S/AS02D into a standard EPI schedule for infants.
Methods: In this phase 2B, single-center, double-blind, controlled trial involving 340 infants in Bagamoyo, Tanzania, we randomly assigned 340 infants to receive three doses of either the RTS,S/AS02D vaccine or the hepatitis B vaccine at 8, 12, and 16 weeks of age.